NCT01899833View on ClinicalTrials.gov

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 10, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Coronary Artery Disease
Interventions
DIAGNOSTIC_TEST

99mTc-Sestamibi

An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.

Trial Locations (1)

73210

Tom Hennebry, MD, Oklahoma City

Sponsors

Lead Sponsor

Cell>Point LLC
All Listed Sponsors
lead

Cell>Point LLC

INDUSTRY

NCT01899833 - Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD) | Biotech Hunter | Biotech Hunter